

Reversal of the respiratory effect of morphine and morphine-6-glucuronide by naloxone: a clinical study using healthy volunteers

Submission date 03/07/2006	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 04/07/2006	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 26/03/2021	Condition category Respiratory	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Albert Dahan

Contact details
Leiden University Medical Center (LUMC)
Department of Anesthesiology
P.O. Box 9600
Leiden
Netherlands
2300 RC
-
adahan@lumc.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Reversal of the respiratory effect of morphine and morphine-6-glucuronide by naloxone: a clinical study using healthy volunteers

Study objectives

This is a pharmacological study to examine the ability to reverse respiratory depression from opioids such as morphine and Morphine-6-Glucuronide (M6G) using low-dose naloxone.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval received by the Ethics Committee of Leiden University Medical Center on the 6th July 2005 (ref: P04.004).

Study design

Randomised, parallel, placebo-controlled, double-blinded trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Respiratory depression by opioids

Interventions

Measurement of respiration on a breath-to-breath basis. We will study four groups, with 12 subjects per group:

1. Group one will receive M6G 0.2 mg/ kg
2. Group two will receive M6G 0.4 mg/kg
3. Group three will receive morphine 0.15 mg/kg
4. Group four will receive morphine 0.3 mg/kg

These opioids will be administered intravenously as a bolus dose, 90 minutes after the opioid infusion, naloxone will be infused using a target controlled infusion system for one hour. Next measurement will continue for another two hours. The opioid doses to be used are based on previous studies as well on clinical efficacy.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Naloxone, morphine, morphine-6-glucuronide

Primary outcome measure

Minute ventilation and pain response to heat pain

Secondary outcome measures

No secondary outcome measures

Overall study start date

01/01/2005

Completion date

01/01/2007

Eligibility**Key inclusion criteria**

Healthy volunteers over 18 years of age

Participant type(s)

Healthy volunteer

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

60

Total final enrolment

24

Key exclusion criteria

1. Obesity (Body Mass Index [BMI] more than 30)
2. Presence of medical disease (heart, lung, liver, kidney, neurological disease, diabetes, pyrosis, diaphragmatic hernia)
3. Presence of psychiatric disease
4. History of chronic alcohol or drug use
5. Allergy to study medications
6. Possibility of pregnancy
7. Lactating females

Date of first enrolment

01/01/2005

Date of final enrolment

01/01/2007

Locations**Countries of recruitment**

Netherlands

Study participating centre

Leiden University Medical Center (LUMC)

Leiden

Netherlands

2300 RC

Sponsor information**Organisation**

Leiden University Medical Centre (LUMC) (The Netherlands)

Sponsor details

Albinusdreef 2

P.O. Box 9600

Leiden

Netherlands

2300 RC

Sponsor type

Hospital/treatment centre

Website

<http://www.lumc.nl/>

ROR

<https://ror.org/027bh9e22>

Funder(s)

Funder type

Industry

Funder Name

CeNes Ltd (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		01/06/2010	26/03/2021	Yes	No